Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleZepbound is considered one of the most powerful options, leading to an average weight reduction of nearly 21 percent body weight after 72 weeks (Reuters)Millions of Americans enrolled in Medicare now have access to GLP-1 weight loss drugs for $50 a month through a temporary pilot program known as the Medicare GLP-1 Bridge.Novo Nordisk's Wegovy in injection or pill form and Eli Lilly's Zepbound four-dose KwikPen injection and Foundayo pill will be available for the low monthly fee through the end of 2027. The program will not cover single-dose Zepbound vials or pens medications.Eligibility is extended to Medicare Part D enrollees whose health is at risk due to obesity, prediabetes, or a history of heart problems, but excludes individuals with existing GLP-1 coverage.To obtain the drugs, patients need a doctor's prescription, completion of a prior authorization process, and certification from their provider that the GLP-1 drug is part of a lifestyle program emphasizing diet and exercise.The program, operating under federal authority to run a temporary “demonstration” project due to existing laws prohibiting Medicare coverage of these drugs, is valid through December 31, 2027, with its long-term future and patient access post-expiration currently unclear.In fullMedicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay.Thank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.

Popular Novo Nordisk and Eli Lilly drugs are included

For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 monthly copay.

The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.

Popular Novo Nordisk and Eli Lilly drugs are included

El sistema de salud pública financiará terapias contra la obesidad mediante un programa piloto de 18 meses. Conoce cuándo entra en vigor el beneficio y quiénes califican

The program, which will make weight loss drugs eligible for people on Medicare for $50 a month, is only set to run for 18 months.

Medicare enrollees as of July 1 can get GLP-1s covered by Part D prescription insurance as part of a trial program until the end of 2027.

Some Medicare beneficiaries are getting access to weight loss drugs this month through a so-called Bridge program. But questions remain regarding the pilot and its cost.

For the first time, Medicare will cover GLP-1s for obesity-related weight loss, without any other medical conditions.

Starting Wednesday, millions of Medicare-qualifying adults will have access to popular medications for weight loss at deep discounts through a temporary federal program called the…

NEW YORK (AP) — Popular — and expensive — GLP-1 weight loss drugs just got a lot cheaper for many older Americans.

The program creates the first obesity-only Medicare coverage pathway

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

Three ways GLP-1s are about to change America.

Only some of the medications are included